- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05802212
Effect of Metformin on Patients With Polycystic Ovary Syndrome
March 26, 2023 updated by: Peking University Third Hospital
Effect of Metformin Intervention on Patients With Polycystic Ovary Syndrome
The purpose of the study is to understand the effect of Metformin on patients with PCOS.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
This study aims to evaluate the effects of Metformin on reproductive endocrine and reproductive outcomes in women with PCOS, and to explore its underlying mechanisms to provide the intervention strategies for PCOS.
Study Type
Interventional
Enrollment (Actual)
95
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Beijing, China
- Peking University Third Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 40 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Individuals who are 20 to 40 years old, planning to become pregnant or infertile women.
- Individuals who are diagnosed as PCOS according to the revised 2003 Rotterdam diagnostic criteria: if 2 out of 3 criteria are met: 1) Oligo- and/or anovulation; 2) Clinical and/or biochemical signs of hyperandrogenism; 3) Polycystic ovaries, and exclusion of other aetiologies (congenital adrenal hyperplasia, androgen-secreting tumors, Cushing's syndrome).
- Individuals who can insist on continuous monitoring in the outpatient clinic. Individuals who are not participating in other research projects currently or 3 months before the intervention.
Exclusion Criteria:
- Individuals who suffering from other diseases that may cause hyperandrogenism and ovulation abnormalities.
- Individuals who are during pregnant, lactation or menopause.
- Individuals who currently receiving weight-loss drugs or surgery or within the past 2 months.
- Individuals who take niacin, nicotinamide, or other vitamin B3-related supplementation currently or within the past 2 months.
- Individuals who need regular medication to treat chronic diseases such as diabetes, hypertension, gout, hyperuricemia, etc.
- Use of medications that affect hormone levels, appetite, carbohydrate absorption, and metabolism within the past 2 months.
- Individuals with severe liver diseases or kidney disease that are ineligible to participate in the study.
- A medical history of severe cardiovascular and cerebrovascular diseases.
- Individuals who currently suffer from severe gastrointestinal diseases or undergo gastrointestinal resection that may affect nutrient absorption.
- Individuals who drink more than 15g of alcohol per day or have a smoking habit.
- Individuals who need drug treatment for any mental illness such as epilepsy and depression.
- Cancer patients.
- Individuals who suffer from infectious diseases such as hepatitis B, active tuberculosis, AIDS, etc.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Metformin intervention for 12 weeks
|
PCOS patients were treated with metformin orally for 12 weeks, and various indicators related to fertility were observed.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The species and genus abundance changes of fungi and bacteria gut microbiota composition
Time Frame: before and after 2, 12 weeks of intervention
|
Determination the species and genus abundance changes of gut microbiota among before and after intervention by ITS genomic
|
before and after 2, 12 weeks of intervention
|
The alterations of secondary metabolites of gut fungi and bacteria
Time Frame: before intervention
|
Determination the alterations of secondary metabolites of gut fungi and bacteria before and after metformin intervention by metabolomics
|
before intervention
|
The alterations of secondary metabolites of gut fungi and bacteria
Time Frame: after 2 weeks of intervention
|
Determination the alterations of secondary metabolites of gut fungi and bacteria before and after metformin intervention by metabolomics
|
after 2 weeks of intervention
|
The alterations of secondary metabolites of gut fungi and bacteria
Time Frame: after 12 weeks of intervention
|
Determination the alterations of secondary metabolites of gut fungi and bacteria before and after metformin intervention by metabolomics
|
after 12 weeks of intervention
|
Blood sugar level
Time Frame: before and after 2, 12 weeks of intervention
|
Changes in plasma glucose concentration after the intervention.
|
before and after 2, 12 weeks of intervention
|
Fasting insulin
Time Frame: before and after 2, 12 weeks of intervention
|
Changes in plasma insulin concentration after the intervention.
|
before and after 2, 12 weeks of intervention
|
Prolactin in serum
Time Frame: before and after 2, 12 weeks of intervention
|
Changes of prolactin(ng/mL) in serum after the intervention.
|
before and after 2, 12 weeks of intervention
|
Follicular stimulating hormone in serum
Time Frame: before and after 2, 12 weeks of intervention
|
Changes of follicular stimulating hormone(mIU/mL) in serum after the intervention.
|
before and after 2, 12 weeks of intervention
|
Luteinizing hormone in serum
Time Frame: before and after 2, 12 weeks of intervention
|
Changes of luteinizing hormone(mIU/mL) in serum after the intervention.
|
before and after 2, 12 weeks of intervention
|
Estradiol in serum
Time Frame: before and after 2, 12 weeks of intervention
|
Changes of estradiol(pmol/L) in serum after the intervention.
|
before and after 2, 12 weeks of intervention
|
Testosterone in serum
Time Frame: before and after 2, 12 weeks of intervention
|
Changes of testosterone(nmol/L) in serum after the intervention.
|
before and after 2, 12 weeks of intervention
|
4-Androstenedione in serum
Time Frame: before and after 2, 12 weeks of intervention
|
Changes of 4-Androstenedione(pmol/L) in serum after the intervention.
|
before and after 2, 12 weeks of intervention
|
The alterations of plasma lipid metabolites
Time Frame: before intervention
|
Determination the alterations of lipid metabolites before and after metformin intervention by metabolomics.
|
before intervention
|
The alterations of plasma lipid metabolites
Time Frame: after 2 weeks of intervention
|
Determination the alterations of lipid metabolites before and after metformin intervention by metabolomics.
|
after 2 weeks of intervention
|
The alterations of plasma lipid metabolites
Time Frame: after 12 weeks of intervention
|
Determination the alterations of lipid metabolites before and after metformin intervention by metabolomics.
|
after 12 weeks of intervention
|
Ovarian volume
Time Frame: before intervention
|
The size of each ovary will be determined using transvaginal ultrasonography for each participant in early follicular phase.
|
before intervention
|
Ovarian volume
Time Frame: after 12 weeks of intervention
|
The size of each ovary will be determined using transvaginal ultrasonography for each participant in early follicular phase.
|
after 12 weeks of intervention
|
Follicle number
Time Frame: before intervention
|
The number of all antral follicles in each ovary will be determined using transvaginal ultrasonography for each participant.
|
before intervention
|
Follicle number
Time Frame: after 12 weeks of intervention
|
The number of all antral follicles in each ovary will be determined using transvaginal ultrasonography for each participant.
|
after 12 weeks of intervention
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Qiaojie, Professor, Peking University Third Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 1, 2021
Primary Completion (Actual)
June 1, 2022
Study Completion (Actual)
February 1, 2023
Study Registration Dates
First Submitted
February 6, 2023
First Submitted That Met QC Criteria
March 26, 2023
First Posted (Actual)
April 6, 2023
Study Record Updates
Last Update Posted (Actual)
April 6, 2023
Last Update Submitted That Met QC Criteria
March 26, 2023
Last Verified
January 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- M2021385
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries
-
Mansoura UniversityNot yet recruitingPCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries
-
Zagazig UniversityCompletedPCOS (Polycystic Ovary Syndrome) of Bilateral OvariesEgypt
-
Cairo UniversityCompleted
-
EgymedicalpediaRecruitingPCOS (Polycystic Ovary Syndrome) of Bilateral OvariesEgypt
-
Fudan UniversityRecruitingDepression, Anxiety | PCOS (Polycystic Ovary Syndrome) of Bilateral OvariesChina
-
Cornell UniversityLaidlaw Foundation; Epperson Fund; Beck Fellowship; Dan Cane FundCompletedPolycystic Ovary Syndrome | Ovarian Cysts | PCOS | Dysmenorrhea | Menstrual Pain | Premenstrual Dysphoric Disorder | Premenstrual Syndrome | Period Pain | Menstrual Problem | PMS | Menstrual Discomfort | Dysmenorrhea Primary | Cramps | Menstrual Cycle Abnormal | PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries | Period... and other conditionsUnited States
-
EgymedicalpediaCompletedPCOS (Polycystic Ovary Syndrome) of Bilateral OvariesEgypt
-
Khyber Medical University PeshawarUniversity of CagliariRecruitingInfertility, Female | PCOS (Polycystic Ovary Syndrome) of Bilateral OvariesPakistan
-
Affiliated Hospital of Nantong UniversityEnrolling by invitationT2D | PCOS (Polycystic Ovary Syndrome) of Bilateral OvariesChina
-
University of Colorado, DenverEunice Kennedy Shriver National Institute of Child Health and Human Development...RecruitingObese | PCOS (Polycystic Ovary Syndrome) of Bilateral OvariesUnited States
Clinical Trials on Metformin intervention for 12 weeks
-
Sigma Theta Tau InternationalRecruiting
-
Guangzhou JOYO Pharma Co., LtdChengdu JOYO pharma Co., Ltd.Not yet recruitingModerate-to-severe Atopic Dermatitis
-
AstraZenecaCompletedMultiple System Atrophy, MSAUnited States, Finland, Austria, France, Sweden, United Kingdom, Italy
-
Nottingham Trent UniversityUniversity of ReadingRecruitingPhysical InactivityUnited Kingdom
-
KeyBioscience AGNordic Bioscience A/SCompletedType 2 Diabetes MellitusDenmark, Czechia, Poland, Moldova, Republic of, Romania, United Kingdom
-
Universidad Pablo de OlavideUnknownExercise Therapy | Severe Mental IllnessSpain
-
Cairo UniversityCompletedMetabolic Syndrome in WomenEgypt
-
Rambam Health Care CampusCompleted
-
Aarhus University Hospital SkejbyInstitute for Clinical and Experimental MedicineCompletedHeart Failure | Coronary Heart Disease | Ischemic Heart DiseasesDenmark
-
Virginia Commonwealth UniversityNational Heart, Lung, and Blood Institute (NHLBI)CompletedHeart FailureUnited States